Skip to main content

Table 4 Longitudinal outcomes in YMRS and HAM-D: monotherapy versus aggregated combination therapies

From: A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder

Predictors YMRS HAM-D
Estimates CI p Estimates CI p
Group [combination] 0.39 − 2.69–3.47 0.802 1.41 − 1.32–4.15 0.307
Time [days] − 0.13 − 0.17 to − 0.08 < 0.001*** − 0.05 − 0.09 to − 0.02 0.005**
Site [VA] 0.37 − 3.34–4.07 0.844 − 4.59 − 8.08 to − 1.11 0.011*
Group [combination] × time − 0.02 − 0.08–0.04 0.443 0.02 − 0.03–0.07 0.359
  1. Monotherapy: divalproex plus placebo; combination: combination therapy of divalproex plus blinded lithium and divalproex plus blinded quetiapine
  2. VA Palo Alto
  3. *p < 0.05, **p < 0.01, ***p < 0.001